Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Covidien Fentanyl Transdermal System patch obtains FDA approval

Covidien, a global provider of healthcare products, reported that Mallinckrodt, a Covidien company, has received US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) for its Fentanyl Transdermal System (FTS) patch.

Covidien’s FTS patch is a generic alternative to the branded DURAGESIC patch of Johnson and Johnson.

FTS, a Class II controlled substance, is an opioid analgesic indicated in opioid-tolerant patients for management of persistent, moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.

Covidien expects to launch FTS in the US in 25mcg/hr, 50mcg/hr, 75mcg/hr and 100mcg/hr strengths in the current quarter.

The plan is designed to minimize abuse and overdose, and includes patient and physician education material, a medication guide, and other tools to ensure patients who receive FTS understand the risks, appropriate use, storage, application and disposal of FTS.